Abstract
AbstractLate-stage relapse (LSR) in patients with breast cancer (BC) occurs more than five years and up to 10 years after initial treatment and has less than 30% 5-year relative survival rate. Long non-coding RNAs (lncRNAs) play important roles in BC yet have not been studied in LSR BC. Here, we identify 1127 lncRNAs differentially expressed in LSR BC via transcriptome sequencing and analysis of 72 early-stage and 24 LSR BC patient tumors. Decreasing expression of the most up-regulated lncRNA, LINC00355, in BC and MCF7 long-term estrogen deprived cell lines decreases cellular invasion and proliferation. Subsequent mechanistic studies show that LINC00355 binds to MENIN and changes occupancy at the CDKN1B promoter to decrease p27Kip. In summary, this is a key study discovering lncRNAs in LSR BC and LINC00355 association with epigenetic regulation and proliferation in BC.
Funder
Susan G. Komen
WUSTL | Washington University School of Medicine in St. Louis
Breast Cancer Research Foundation
Cancer Prevention and Research Institute of Texas
Avon Foundation for Women
Robert and Janice McNair Foundation
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology
Reference77 articles.
1. Siegel, R. L. et al. Colorectal cancer statistics, 2020. CA: Cancer J. Clin. 70, 145–164 (2020).
2. Cronin, K. A. et al. Annual report to the nation on the status of cancer, part I: National Cancer Statistics. Cancer 124, 2785–2800 (2018).
3. Omidvari, S. et al. Very late relapse in breast cancer survivors: a report of 6 cases. Iran. J. Cancer Prev. 6, 113–117 (2013).
4. Pan, H. et al. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). J. Clin. Oncol. 34, 505–505 (2016).
5. Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846 (2017).